Anti-hepatitis C composition and method for preparing drugs for inhibiting hepatitis C virus or treating hepatitis C

A technology for hepatitis C virus and hepatitis C, which is applied in antiviral agents, pharmaceutical formulas, medical preparations containing active ingredients, etc., and can solve problems such as hepatitis C of unknown limonoid compounds

Inactive Publication Date: 2011-03-30
IND TECH RES INST
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, it is still unclear whether limonoid compounds can effectively inhibit hepatitis C

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-hepatitis C composition and method for preparing drugs for inhibiting hepatitis C virus or treating hepatitis C
  • Anti-hepatitis C composition and method for preparing drugs for inhibiting hepatitis C virus or treating hepatitis C
  • Anti-hepatitis C composition and method for preparing drugs for inhibiting hepatitis C virus or treating hepatitis C

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Extraction of effective components for inhibiting hepatitis C virus from plant materials

[0066] Dissolve 5.96g of toosendan alcohol extract in 20ml of mixed solvent of methanol and water, and extract 2-3 times with 15ml each of n-hexane, diethyl ether, dichloromethane and ethyl acetate respectively to obtain n-hexane layers extract, diethyl ether layer extract, dichloromethane layer extract and ethyl acetate layer extract. The extracts of each layer were concentrated and dried to obtain the n-hexane layer extract, the ether layer extract, the dichloromethane layer extract and the ethyl acetate layer extract respectively, and these extracts were respectively treated with Huh-luc / neo-ET cells ( HCV Cell Replication System) to test the activity of these extracts against HCV.

[0067] The results show that the gained ether layer extract (1.113g) has the activity of inhibiting the replication of hepatitis C virus, and its inhibitory concentration (IC) to 50% hepatitis C v...

Embodiment 2

[0080] 1. Toxicity test of toosendanin on Huh-luc / neo-ET cells

[0081] Huh-luc / neo-ET cells in 2.5×10 4 Cells / 100 μl / well were seeded in 96-well cell culture plates (Corning Incorporation COSTAR, 3599) and cultured in a cell culture incubator (NUAIR nu-5510).

[0082] The next day, dilute the toosendanin samples with DMEM culture solution to concentrations of 28.73μg / ml, 9.57μg / ml, 3.19μg / ml, 1.06μg / ml, 0.35μg / ml, 0.11μg / ml, 0.039μg / ml Different from 0.013μg / ml, or diluted to 114.92μg / ml, 38.33μg / ml, 12.77μg / ml, 4.25μg / ml, 1.42μg / ml, 0.46μg / ml, 0.16μg / ml and 0.057μg / ml Toosendanin culture solution with diluted concentration, and the original culture solution in the 96-well plate was sucked off by a vacuum pump (DOAT-704AA). During this process, care must be taken not to suck the cells. Then add toosendanin culture solution of the above concentration in the amount of 100 μl / well to the above-mentioned 96-well cell culture plate containing cells as the experimental group, and...

Embodiment 3

[0094] 1. Toxicity test of Trinortriterpene H (Trichilin H) on Huh-luc / neo-ET cells

[0095] The experimental procedure is the same as in Example 2, and the test sample is replaced by tetranortriterpene H. Among them, tetranortriterpene H samples were diluted with DMEM culture medium to concentrations of 50 μg / ml, 25 μg / ml, 8.33 μg / ml, 2.78 μg / ml, 0.93 μg / ml, 0.31 μg / ml, 0.1 μg / ml and 0.03 μg / ml tetranortriterpene H culture solution.

[0096] The results are shown in Table 1. The 50% lethal concentration of tetranortriterpene H to cells (CC 50 ) greater than 50μg / ml, 15% lethal concentration (CC 15 ) was 0.7 μg / ml.

[0097] 2. Test the fluorescence activity of fireflies to evaluate the effect of trinortriterpene H (Trichilin H) on inhibiting the replication of hepatitis C virus

[0098] The experimental procedure is the same as in Example 2, and the test sample is replaced by tetranortriterpene H. Huh-luc / neo-ET cells were co-cultured with tetranortriterpene H at concent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an anti-hepatitis C composition which comprises therapeutically effective dose of limonoid compound or pharmaceutical salts thereof, the molecular formula of the limonoid compound is shown as formula (I), wherein R1 is H or OAc, and R2 is H or COCH(CH3)2; the composition further comprises a pharmaceutical carrier; and the anti-hepatitis C composition is used for inhibiting hepatitis C virus or treating hepatitis C. The invention further comprises a method for preparing drugs for inhibiting the hepatitis C virus or treating the hepatitis C. (Formula I).

Description

technical field [0001] The present invention relates to an anti-hepatitis C composition, and in particular to a composition containing a limonoid compound, which can be used for inhibiting hepatitis C virus or treating hepatitis C. Background technique [0002] 2-3% (about 300,000,000 people) of the population is infected with hepatitis C in the whole world, and it spreads at a rate of 3-4,000,000 new patients every year. At present, the only proven and approved anti-HCV drug is alpha (alpha) interferon (α-Interferon), and ribavirin is proven and approved to strengthen the anti-hepatitis C virus of alpha interferon. efficacy of hepatitis virus. However, both of them will produce serious side effects, and most of them have the phenomenon of drug resistance. [0003] The basic structure of the limonoid compound is three six-membered rings plus one five-membered ring, and then connected with the furan ring by a single bond. They mainly exist in citrus, Rutaceae (Rutaceae) an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P31/14
Inventor 李连滋张秀凤蔡蕙冰郭宗铿钟振方
Owner IND TECH RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap